RxDoctor Payments Data

Emily Monnette

Family · Chattanooga, TNNPI 1457713075

Payments from drug & device makers

$7,950in general payments, 2019–2025

Across 495 payments — averaging $16.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$557
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$438
  • Lilly USA, LLC$432
  • Takeda Pharmaceuticals U.S.A., Inc.$332
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,950100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,950 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$19,846
Medicare patients
79
Services billed
352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide67$97,858
OzempicSemaglutide63$89,830
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$57,215
TrulicityDulaglutide52$56,890
JardianceEmpagliflozin36$48,772
FarxigaDapagliflozin Propanediol31$40,449
EliquisApixaban23$27,496
XareltoRivaroxaban21$22,402
LinzessLinaclotide18$20,100
Repatha SureclickEvolocumab24$19,936
Tresiba Flextouch U-200Insulin Degludec19$11,735
Atorvastatin Calcium166$2,045
Rosuvastatin Calcium133$1,727
Albuterol Sulfate HfaAlbuterol Sulfate47$1,653
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,516

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$432$154,748119 claims
Novo NordiskOzempic$1,231$89,83063 claims
GSKTrelegy Ellipta$109$57,21554 claims
Boehringer IngelheimJardiance$31$48,77236 claims
AstraZenecaFarxiga$557$40,44931 claims
PfizerEliquis$244$27,49623 claims
Johnson & JohnsonXarelto$125$22,40221 claims
AbbVieLinzess, Synthroid$2,088$20,80732 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$59387 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →